| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Meetings and Conferences |
|
|
| |
| |
| |
May 09, 2023 |
|
|
| |
|
|
| |
|
|
|
Xtalks, online
2023 -5-18
Antibody drug discovery — starting from target identification & generation, lead validation & optimizations, preclinical candidate selection to clinical phases — is an arduous and challenging process. Advanced antibody discovery platforms and innovative techniques for antibody functional screening contribute to accelerating and improving the success rates in current therapeutics development. Once the drug candidate is identified, stringent efficacy and safety evaluations are essential from preclinical to clinical stage. An anti-idiotypic antibody is capable of binding to antibody drugs within biological fluids, therefore they are commonly used to validate drug efficacy through pharmacokinetics and pharmacodynamics kinetic assays and also used to evaluate drug safety by measuring the antibody drug immunogenicity through anti-drug antibody assays.
In this webinar, the featured speaker will discuss:
An overview of anti-idiotypic antibodies in antibody drug discovery
Overcoming the timeline challenges in antibody drug discovery with anti-idiotypic antibody platforms
Elaborate on successful case studies in current popular therapeutics such as antibody drug conjugates, single-chain variable fragments (scFv), VHH antibody, bi-specific antibody, etc.
Strategies and advantages of anti-drug antibody assays and pharmacokinetic ELISA kit development
Join this webinar to learn how anti-idiotypic antibody platforms accelerate drug discovery.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Hui Foon Tan, Global Product Manager, GenScript
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -5-18
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|